Novo NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of denecimig (Mim8) for the treatment of hemophilia A, with or without inhibitors, in adults and children. Denecimig is a next-generation factor VIIIa (FVIIIa) mimetic bispecific antibody designed to prevent or reduce bleeding episodes through routine prophylactic treatment. The therapy is designed to offer flexible dosing options, including once-monthly, every-two-week and weekly administration. It is administered subcutaneously and is being developed as a prefilled pen, which could provide greater convenience compared with conventional treatment approaches.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.